Przejdź do zawartości
Merck
Wszystkie zdjęcia(1)

Key Documents

SRP2151

Sigma-Aldrich

HCV-NS4A/NS3-1b Protease, Histag, strain HC-J4 from hepatitis C virus

recombinant, expressed in E. coli, ≥80% (SDS-PAGE)

Synonim(y):

Hepatitis C virus NS3 protease, NS3, NS4ANS3 complex, pfam02907

Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych


About This Item

Kod UNSPSC:
12352204
NACRES:
NA.26

pochodzenie biologiczne

hepatitis C virus

rekombinowane

expressed in E. coli

Próba

≥80% (SDS-PAGE)

Postać

frozen liquid

masa cząsteczkowa

~22.7 kDa

opakowanie

pkg of 10 μg

stężenie

500 μg/mL

kolor

colorless to clear

numer dostępu NCBI

Warunki transportu

dry ice

temp. przechowywania

−70°C

informacje o genach

hepatitis C virus ... HCVgp1(951475)

Działania biochem./fizjol.

Persistent infection with hepatitis C virus (HCV) is a common cause of chronic liver disease, including chronic hepatitis, cirrhosis, and hepatocellular carcinoma. HCV is an enveloped, single-stranded RNA virus with a 9.6-kb positive-polarity genome, which encodes a polyprotein precursor of about 3,000 amino acids. The HCV polyprotein is proteolytically processed by cellular and HCV proteases into at least 10 distinct products. NS3 serine protease and helicase as well as NS5B RNA-dependent RNA polymerase are believed to be components of a replication complex responsible for viral RNA replication and have been shown to be essential for the HCV replication in chimpanzees. These HCV enzymes have been the major targets for the development of HCV-specific therapeutics during the past decade. The HCV NS3/4A protease is responsible for cleavage at four sites within the HCV polyprotein to generate the N termini of the NS4A, NS4B, NS5A, and NS5B proteins. It has been shown that the central region (amino acids 21-30) of the 54-residue NS4A protein is essential and sufficient for the enhancement of proteolytic activity of the NS3 serine protease. In recent phase I trials, a 2-3-log reduction of HCV viral load was observed after a 2-day treatment with a serine protease inhibitor, which provided the first proof-of-concept evidence that HCV NS3/4A protease inhibitors could be a new therapeutic option for hepatitis C patients.

Postać fizyczna

Clear and colorless frozen liquid solution

Uwaga dotycząca przygotowania

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. While working, please keep sample on ice.
This page may contain text that has been machine translated.

Kod klasy składowania

10 - Combustible liquids

Klasa zagrożenia wodnego (WGK)

WGK 1

Temperatura zapłonu (°F)

Not applicable

Temperatura zapłonu (°C)

Not applicable


Certyfikaty analizy (CoA)

Poszukaj Certyfikaty analizy (CoA), wpisując numer partii/serii produktów. Numery serii i partii można znaleźć na etykiecie produktu po słowach „seria” lub „partia”.

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów

A A Kolykhalov et al.
Journal of virology, 74(4), 2046-2051 (2000-01-22)
Hepatitis C virus (HCV) infection is a widespread major human health concern. Significant obstacles in the study of this virus include the absence of a reliable tissue culture system and a small-animal model. Recently, we constructed full-length HCV cDNA clones
Blight, K. J., et al.
Antiviral Ther., 3, 71-81 (1998)
M J Alter
Hepatology (Baltimore, Md.), 26(3 Suppl 1), 62S-65S (1997-09-26)
In the United States, the annual number of newly acquired acute hepatitis C virus (HCV) infections has declined from an estimated 180,000 in the mid 1980s to an estimated 28,000 in 1995. Approximately 25% to 30% of these infections are

Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.

Skontaktuj się z zespołem ds. pomocy technicznej